Replicon System for Lassa Virus
Open Access
- 15 December 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (24) , 13793-13803
- https://doi.org/10.1128/jvi.78.24.13793-13803.2004
Abstract
Lassa virus is endemic to West Africa and causes hemorrhagic fever in humans. To facilitate the functional analysis of this virus, a replicon system was developed based on Lassa virus strain AV. Genomic and antigenomic minigenomes (MG) were constructed consisting of the intergenic region of S RNA and a reporter gene ( Renilla luciferase) in antisense orientation, flanked by the 5′ and 3′ untranslated regions of S RNA. MGs were expressed under the control of the T7 promoter. Nucleoprotein (NP), L protein, and Z protein were expressed from plasmids containing the T7 promoter and internal ribosomal entry site. Transfection of cells stably expressing T7 RNA polymerase (BSR T7/5) with MG in the form of DNA or RNA and plasmids for the expression of NP and L protein resulted in high levels of Renilla luciferase expression. The replicon system was optimized with respect to the ratio of the transfected constructs and by modifying the 5′ end of the MG. Maximum activity was observed 24 to 36 h after transfection with a signal-to-noise ratio of 2 to 3 log units. Northern blot analysis provided evidence for replication and transcription of the MG. Z protein downregulated replicon activity close to background levels. Treatment with ribavirin and alpha interferon inhibited replicon activity, suggesting that both act on the level of RNA replication, transcription, or ribonucleoprotein assembly. In conclusion, this study describes the first replicon system for a highly pathogenic arenavirus. It is a tool for investigating the mechanisms of replication and transcription of Lassa virus and may facilitate the testing of antivirals outside a biosafety level 4 laboratory.Keywords
This publication has 79 references indexed in Scilit:
- Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitroAntiviral Research, 2004
- Role of the Virus Nucleoprotein in the Regulation of Lymphocytic Choriomeningitis Virus Transcription and RNA ReplicationJournal of Virology, 2003
- Characterization of the Genomic Promoter of the Prototypic Arenavirus Lymphocytic Choriomeningitis VirusJournal of Virology, 2003
- Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymeraseFEBS Letters, 1995
- Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cellsJournal of Molecular Biology, 1989
- Lassa FeverNew England Journal of Medicine, 1986
- Ribonucleic acids of Machupo and Lassa virusesArchiv für die gesamte Virusforschung, 1984
- The broad spectrum antiviral agent ribavirin inhibits capping of mRNABiochemical and Biophysical Research Communications, 1979
- Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra LeoneScience, 1974
- Lassa fever Epidemiological aspects of the 1970 epidemic, Jos, NigeriaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1972